CASE REPORT article
Front. Vet. Sci.
Sec. Veterinary Regenerative Medicine
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1603383
Xenogeneic mesenchymal stem cells secretome for the treatment of feline chronic gingivostomatitis
Provisionally accepted
- 1City University of Hong Kong, Kowloon, Hong Kong, SAR China
- 2CityU Veterinary Medical Centre, Kowloon, Hong Kong, SAR China
- 3Hong Kong Regen Medtech Ltd., HKSTP, Hong Kong, Hong Kong, SAR China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This case series describes the treatment of 8 cats with mesenchymal stem cells (MSCs) secretome, a therapeutic modality never used before for refractory feline chronic gingivostomatitis (FCGS). The cats were free of systemic illness and were not on immunomodulators during treatment. All cats received 2 to 3 treatments of MSCs secretome through intramucosal injections given 3 months apart. White cell count and globulins, stomatitis disease activity index (SDAI) and histopathology were used pre and post treatment to assess the response to treatment.Of the 8 selected cases, resolution of clinical signs and significant improvement of lesions were reported in 2 cats. Six cats did not have a substantial clinical response, and lesions remained mostly unchanged. Six cats had a reduction in globulins and 5 cats increased in weight respectively after treatment. SDAI decreased in all the cats treated. The 2 cats that had resolution of clinical signs had the most significant decrease in serum globulins and SDAI, and both increased in weight.No adverse effects or chemistry and haematological abnormalities directly associated with the use of MSCs secretome were observed in any of the cats, suggesting human derived MSCs secretome can be safely used in cats. Increases in weight, and reductions of SDAI and globulinemia were observed in a subset of cats after treatment, suggesting an immunomodulatory effect and downregulation of proinflammatory factors. Well-designed clinical trials are recommended to verify the observed effects in this study and to evaluate long-lasting clinical benefits, or potential side effects of the treatment.
Keywords: feline chronic gingivostomatitis, Immunomodulation, Mesenchymal Stem Cells, oral mucosa, Secretome, supernatant, Xenogeneic
Received: 04 Apr 2025; Accepted: 27 May 2025.
Copyright: © 2025 Almendros, Nekouei, Moores, Jesky, Baiker and Tse. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Angel Almendros, City University of Hong Kong, Kowloon, Hong Kong, SAR China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.